A Wolowski1, T Eger2, R Braas3, J Gohr2, N Weber4, K Witanski4, F Wörner2. 1. Poliklinik für Prothetische Zahnmedizin und Biomaterialien, Bereich Psychosomatik und Psychopathologie in der Zahnheilkunde, Zentrum für Zahn-, Mund- und Kieferheilkunde, Albert-Schweitzer-Campus 1/W30, Zentrum ZMK, D 48149, Münster, Germany. wolowsk@uni-muenster.de. 2. Abt. XXIII, Zahnmedizin, Parodontologie und Truppenzahnmedizin Bundeswehrzentralkrankenhaus Koblenz, Rübenacherstr. 170, D 56072, Koblenz, Germany. 3. Abt VI, Zentrum für seelische Gesundheit, Bundeswehrzentralkrankenhaus Koblenz, Rübenacherstr. 170, D 56072, Koblenz, Germany. 4. Poliklinik für Prothetische Zahnmedizin und Biomaterialien, Bereich Psychosomatik und Psychopathologie in der Zahnheilkunde, Zentrum für Zahn-, Mund- und Kieferheilkunde, Albert-Schweitzer-Campus 1/W30, Zentrum ZMK, D 48149, Münster, Germany.
Abstract
OBJECTIVES: The aim of a pilot study was to clarify the question of whether mouth opening restrictions in patients with PTSD by means of splint therapy (st) show long-term therapeutic effects in the case of functional disorders. MATERIAL AND METHODS: In 31 of 36 inpatients (soldiers, average age 37.1 ± 7.3 years, 26.7 ± 2.1 teeth) with confirmed posttraumatic stress disorder, chronic pain intensity > 6 (visual analogue scale 0 to 10), the mouth opening was determined, and the functional status (RDC-TMD) was recorded. All participants received a splint that was worn at night. A control of the therapeutic effect of the splint occurred after 6 weeks, 3, 6, and 12 months. RESULTS: The mouth opening initially had an average of 30.9 ± 6.5 mm (median 31 mm). The pain intensity (PI) was reported to be on average VAS 8.3 ± 0.9, the chronic degree of pain according to von Korff was 3.9 ± 03. Six weeks after the st (n = 31), the average mouth opening was 49.5 ± 6.3 mm (median 51.5). PI was given as VAS 2.3 ± 1.1 on average. After 3, 6, and 12 months, 24, 15, and 14 subjects could be interviewed regarding PI. Based on the last examination date of all subjects, the average PI was given as 1.1 ± 0.9 (median 1). CONCLUSION: The presented data show that the therapeutic short-term results achieved by means of a splint remain valid on the long term despite continued PTSD. CLINICAL RELEVANCE: The presented study shows that patients will benefit in the long term from a splint and remain symptom-free, even if this mental illness persists.
OBJECTIVES: The aim of a pilot study was to clarify the question of whether mouth opening restrictions in patients with PTSD by means of splint therapy (st) show long-term therapeutic effects in the case of functional disorders. MATERIAL AND METHODS: In 31 of 36 inpatients (soldiers, average age 37.1 ± 7.3 years, 26.7 ± 2.1 teeth) with confirmed posttraumatic stress disorder, chronic pain intensity > 6 (visual analogue scale 0 to 10), the mouth opening was determined, and the functional status (RDC-TMD) was recorded. All participants received a splint that was worn at night. A control of the therapeutic effect of the splint occurred after 6 weeks, 3, 6, and 12 months. RESULTS: The mouth opening initially had an average of 30.9 ± 6.5 mm (median 31 mm). The pain intensity (PI) was reported to be on average VAS 8.3 ± 0.9, the chronic degree of pain according to von Korff was 3.9 ± 03. Six weeks after the st (n = 31), the average mouth opening was 49.5 ± 6.3 mm (median 51.5). PI was given as VAS 2.3 ± 1.1 on average. After 3, 6, and 12 months, 24, 15, and 14 subjects could be interviewed regarding PI. Based on the last examination date of all subjects, the average PI was given as 1.1 ± 0.9 (median 1). CONCLUSION: The presented data show that the therapeutic short-term results achieved by means of a splint remain valid on the long term despite continued PTSD. CLINICAL RELEVANCE: The presented study shows that patients will benefit in the long term from a splint and remain symptom-free, even if this mental illness persists.
Authors: Patricia A Resick; Jennifer Schuster Wachen; Katherine A Dondanville; Kristi E Pruiksma; Jeffrey S Yarvis; Alan L Peterson; Jim Mintz; Elisa V Borah; Antoinette Brundige; Elizabeth A Hembree; Brett T Litz; John D Roache; Stacey Young-McCaughan Journal: JAMA Psychiatry Date: 2017-01-01 Impact factor: 21.596
Authors: Dean Ajdukovic; Dea Ajdukovic; Marija Bogic; Tanja Franciskovic; Gian Maria Galeazzi; Abdulah Kucukalic; Dusica Lecic-Tosevski; Matthias Schützwohl; Stefan Priebe Journal: PLoS One Date: 2013-08-07 Impact factor: 3.240
Authors: Tobias Ficnar; Claudius Middelberg; Bernd Rademacher; Stefan Hessling; Raphael Koch; Ludger Figgener Journal: Head Face Med Date: 2013-01-25 Impact factor: 2.151